A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficancy of MK-0518/Raltegravir in a Disease Cohort of HIV-Infected Patients (055-00 MK-0518)02/01/2003 - 01/31/2012 (PI)
Merck & Company, Inc.
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination with an Optimized Background Therapy (OBT), Versus O02/02/2006 - 07/31/2011 (PI)
Merck & Company, Inc.